October Featured Clinical Trials

Learn about featured clinical trials currently enrolling or search our trials database

OMP 1213

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Disease: Pancreas

Objective: To determine the maximum tolerated dose (MTD) of OMP-59R5 when administered every other week (on Days 1 and 15) in combination with nab-paclitaxel 125 mg/m2 and gemcitabine 1000 mg/m2 on Days 1, 8 and 15 of every 28-day cycle in subjects with previously untreated stage IV pancreatic cancer (Phase 1b portion).

NOVA 1Y13

Disease: Solid Tumors

Objective: To assess clinical benefit associated with BKM120 treatment based on local investigator assessment. For patients with solid tumors the assessment criteria will be RECIST 1.1 and will include responses of CR or PR or SD.

NOVA 2Y14 

Disease: Solid Tumors

Objective: To assess clinical benefit associated with MEK162 treatment based on local investigator assessment.
For patients with solid tumors the assessment criteria will be RECIST 1.1 and will include responses of CR or PR or SD.

NOVA 3Y14

Disease: Solid Tumors

Objective: To assess clinical benefit associated with dovitinib treatment based on local investigator assessment.
For patients with solid tumors the assessment criteria will be RECIST 1.1 and will include responses of CR or PR or SD.

CASE 4913

Advertising Policy

Disease: Leukemia

Objective: To determine whether eltrombopag leads to early platelet recovery in older AML patients (> 60 years) who attain morphologic remission on day 14 bone marrow assessment following remission IC.

MEI 1914

Disease: Myelodysplastic Syndrome (MDS)

Objective: Estimate Clinical Improvement rate including Complete Responses (CR), Marrow CR, Partial Responses (PR), Hematologic Improvement (HI) (CR+Marrow CR+PR+HI).

CASE 3413

Disease: Lymphoma, Diffuse Large B Cell

Objective: To determine the safety of carfilzomib in combination with R-CHOP (CR-CHOP) in patients with newly diagnosed DLBCL and identify a recommended phase II dose (RP2D).

ARRY 1A13

Disease: Multiple Myeloma

Objective: Estimate the PFS of patients treated with carfilzomib + ARRY-520 and of patients treated with single-agent carfilzomib.

SEGE 2412

Advertising Policy

Disease: Lymphoma

Objective: To compare the progression-free survival (PFS) as determined by an independent review facility (IRF) between the 2 treatment arms.

CASE 4A13

Disease: Multiple Myeloma

Objective: Define the tolerability and safety of MLN9708 (ixazomib) administered on a day 1,8,15 every 28 day schedule up to 4mg in combination with fixed doses of panobinostat and dexamethasone in patients with relapsed or refractory myeloma.

CLDX 1114

Disease: Breast

Objective: To evaluate the anti-cancer activity of CDX-011 in metastatic, GPNMB over-expressing, triple-negative breast cancer as measured by the objective response rate (ORR) and duration of progression-free survival (PFS).

NSABP B43

Disease: Breast

Objective: The primary aim is to determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing the subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral DCIS (IIBCR-SCR-DCIS) in women with HER2-positive DCIS resected by lumpectomy.